[Zidovudine-associated mitochondriopathy: three possible observations in Abidjan, Côte d'Ivoire].
In Africa, prevention of mother-to-child transmission of HIV (PMTCT) with antiretrovirals is becoming a key component of the response to the pandemic. Toxicity issues remain however a concern and require careful monitoring. We report here three observations of mild neurological deterioration among children for whom a diagnosis of mitochondrial dysfunction was considered possible. These children were identified within a PMTCT research program (ANRS 049) conducted in Abidjan, Côte d'Ivoire, and evaluating a short regimen of maternal zidovudine monotherapy for PMTCT of HIV type 1. Maternal HIV-1 infection was diagnosed during pregnancy before enrolment in the randomised trial (two cases) or in the subsequent open cohort (one case). These three women had been allocated to the ZDV group and had no particular medical history. Pregnancy check-up was negative except the diagnosis of HIV-1 infection. The three children were diagnosed as uninfected by HIV-1. Symptoms developed by the age of six months (two cases) and 13 months (one case): growth failure, anthropometric abnormalities, impaired psycho-motor development, generalised and repeated seizures. The evolution of these three HIV-uninfected children was favourable after 12 to 18 months. The transient nature of these abnormalities is compatible with mild complications of mitochondrial dysfunction. We conclude however that the anticipated benefits of PMTCT with antiretrovirals in Africa greatly outweigh the potential risks and should not lead to reconsider their public health interest
Elenga
N
N
Programme PACCI, CHU de Treichville, BP 2890, Abidjan 18, Côte d'Ivoire. elengafr@yahoo.fr
Msellati
P
P
Fassinou
P
P
Viho
I
I
Dabis
F
F
D000328:Adult; D000747:Anemia, Hypochromic / Q000150:complications; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000494:pharmacology; D015331:Cohort Studies; D015897:Comorbidity; D007560:Cote d'Ivoire / Q000453:epidemiology; D004829:Epilepsy, Generalized / Q000139:chemically induced*; D005183:Failure to Thrive / Q000139:chemically induced*; D005260:Female; D005333:Fetus / Q000187:drug effects*; D006130:Growth Disorders / Q000139:chemically induced; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D007223:Infant; D008297:Male; D008928:Mitochondria / Q000187:drug effects*; D009123:Muscle Hypotonia / Q000139:chemically induced; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy; D011297:Prenatal Exposure Delayed Effects; D011502:Protein-Energy Malnutrition / Q000150:complications; D011596:Psychomotor Disorders / Q000139:chemically induced*; D016032:Randomized Controlled Trials as Topic; D015215:Zidovudine / Q000009:adverse effects* / Q000494:pharmacology
D019380:Anti-HIV Agents; D015215:Zidovudine